Watch our webinar with Paradigm Biopharmaceuticals, featuring Founder and Managing Director Paul Rennie. A presentation followed by live Q&A with the audience.

Paradigm Biopharmaceuticals Ltd. (ASX:PAR) (“Paradigm” or “Company”) is a late-clinical-stage drug development company headquartered in Melbourne, Australia. The Company is focused on delivering new therapies to address unmet medical needs. Paradigm was established in 2014 by Paul Rennie (Chairman and Managing Director) based on the insight that the properties of injectable pentosan polysulfate sodium (PPS) could be beneficially applied to conditions characterized by pain and inflammation.
The Company was listed on the Australian Stock Exchange in August 2015. The Company intends to demonstrate that PPS is a safe and effective treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The primary indication in development is the treatment of pain and improvement in function in knee osteoarthritis.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.